BRK”ing” Down All We Know About PTK6 in Breast Cancer
Date Issued
2018
Author(s)
Yuan, Yi
Ang, Hui Li
Lai, Xianning
Wang, Lingzhi
Pandey, Vijay
Huang, Benjamin BoJun
Tan, Tuan Zea
Chong, Hui Yi
Ong, Philip Zheng Yang
Rangappa, Kanchugarakoppal S.
Arfuso, Frank
Tan, Kevin Shyong-Wei
Basappa, null
Goh, Boon Cher
Sethi, Gautam
Lobie, Peter E.
Kumar, Alan Prem
Abstract
The search for improved therapeutic approaches to breast cancer are still on going. Breast tumor kinase (BRK, also known as PTK6) is one of the targets, it is highly expressed in breast carcinomas while displaying low or no expression in the normal mammary gland, which hints at the oncogenic role of this enzyme in breast cancer. In these twenty years, an increasing number of studies have focused on understanding the cellular roles of BRK in breast cancers. This review outlines the advances made towards understanding the cellular and physiological role of BRK, the molecular and chemical inhibitors and its therapeutic significance in breast cancer.
SDGs
Type
preprint